Revenue
2023
2024
2025
Nuvation Bio Inc. (NUVB)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0 | — | — | — |
| Gross profit | — | $795,000 | $0 | — | — | — |
| Research & development | $115.1M | $99.1M | $71.3M | $87.8M | $69.0M | $32.6M |
| Operating expenses | $276.0M | $600.5M | $99.8M | $119.7M | $93.3M | $43.6M |
| Operating income | −$213.1M | −$592.6M | −$99.8M | −$119.7M | −$93.3M | −$43.6M |
| EBITDAderived | −$211.3M | −$591.9M | −$99.6M | −$119.5M | −$93.1M | −$43.4M |
| Net income | −$204.6M | −$567.9M | −$75.8M | −$104.2M | −$86.8M | −$41.7M |
| Basic EPSper diluted share | -$0.60 | -$2.11 | -$0.35 | -$0.48 | -$0.44 | -$0.43 |
| Diluted EPSper diluted share | -$0.60 | -$2.11 | -$0.35 | -$0.48 | -$0.44 | -$0.43 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 · 10b5-1 | Sauvage PhilippeChief Financial Officer | SellClass A Common Stock | 47.7K | $6.01 | $286.5K | 12.7K |
| Jun 23, 2026Form 4 · 10b5-1 | Markel StacyCHIEF PEOPLE OFFICER | SellClass A Common Stock | 125.0K | $6.03 | $753.8K | 32.6K |
| Jun 23, 2026Form 4 · 10b5-1 | Wentworth KerryCHIEF REGULATORY OFFICER | SellClass A Common Stock | 63.0K | $6.02 | $379.3K | 53.0K |
| Jun 9, 2026Form 4 | Mashal RobertDirector | BuyClass A Common Stock · indirect | 25.0K | $4.73 | $118.3K | 225.0K |
| Apr 17, 2026Form 4 · 10b5-1 | Liu DongfangCHIEF MEDICAL OFFICER | SellClass A Common Stock | 50.0K | $5.02 | $251.0K | 18.0K |